Safety and Immunogenicity of a Novel Recombinant Simian Adenovirus ChAdOx2 as a Vectored Vaccine

Safety and Immunogenicity of a Novel Recombinant Simian Adenovirus ChAdOx2 as a Vectored Vaccine

Adenovirus vectored vaccines are a highly effective strategy to induce cellular immune responses which are particularly effective against intracellular pathogens. Recombinant simian adenovirus vectors were developed to circumvent the limitations imposed by the use of human adenoviruses due to widesp...

Πλήρης περιγραφή

Λεπτομέρειες βιβλιογραφικής εγγραφής
Κύριοι συγγραφείς:	Folegatti, P, Bellamy, D, Roberts, R, Powlson, J, Edwards, N, Mair, C, Bowyer, G, Poulton, I, Mitton, C, Green, N, Berrie, E, Lawrie, A, Hill, A, Ewer, K, Hermon-Taylor, J, Gilbert, S
Μορφή:	Journal article
Έκδοση:	MDPI 2019

Παρόμοια τεκμήρια

Safety and Immunogenicity of a Novel Recombinant Simian Adenovirus ChAdOx2 as a Vectored Vaccine
ανά: Pedro M. Folegatti, κ.ά.
Έκδοση: (2019-05-01)

Lyophilization to enable distribution of ChAdOx1 and ChAdOx2 adenovirus-vectored vaccines without refrigeration
ανά: Zhang, C, κ.ά.
Έκδοση: (2023)

CMV-associated T cell and NK cell terminal differentiation does not impact immunogenicity of ChAdOx1 vaccination
ανά: Sharpe, HR, κ.ά.
Έκδοση: (2022)

Lyophilization to enable distribution of ChAdOx1 and ChAdOx2 adenovirus-vectored vaccines without refrigeration
ανά: Cheng Zhang, κ.ά.
Έκδοση: (2023-06-01)

Stability of Chimpanzee Adenovirus Vectored Vaccines (ChAdOx1 and ChAdOx2) in Liquid and Lyophilised Formulations
ανά: Adam Berg, κ.ά.
Έκδοση: (2021-10-01)

CMV-associated T cell and NK cell terminal differentiation does not affect immunogenicity of ChAdOx1 vaccination
ανά: Hannah R. Sharpe, κ.ά.
Έκδοση: (2022-03-01)

Clinical assessment of a novel recombinant simian adenovirus ChAdOx1 as a vectored vaccine expressing conserved influenza a antigens
ανά: Antrobus, R, κ.ά.
Έκδοση: (2014)

Clinical assessment of a novel recombinant simian adenovirus ChAdOx1 as a vectored vaccine expressing conserved Influenza A antigens.
ανά: Antrobus, R, κ.ά.
Έκδοση: (2014)

Immunogenicity Differences of the ChAdOx1 nCoV-19 Vaccine According to Pre-Existing Adenovirus Immunity
ανά: Jinnam Kim, κ.ά.
Έκδοση: (2023-04-01)

Clinical assessment of ChAdOx1 vectored vaccines against emerging pathogens
ανά: Moreira Folegatti, P
Έκδοση: (2021)

A single dose of ChAdOx1 Chik vaccine induces neutralising antibodies against four chikungunya virus lineages in a phase 1 clinical trial
ανά: Folegatti, P, κ.ά.
Έκδοση: (2021)

Clinical assessment of a recombinant simian adenovirus ChAd63: a potent new vaccine vector.
ανά: O'Hara, G, κ.ά.
Έκδοση: (2012)

Combined intranasal and intramuscular parainfluenza 5-, simian adenovirus ChAdOx1- and poxvirus MVA-vectored vaccines induce synergistically HIV-1-specific T cells in the mucosa
ανά: Ashley C. Beavis, κ.ά.
Έκδοση: (2023-07-01)

Safety and immunogenicity of adenovirus and poxvirus vectored vaccines against a Mycobacterium avium complex subspecies
ανά: Folegatti, P, κ.ά.
Έκδοση: (2021)

Safety and immunogenicity of ChAdOx1 MERS Vaccine Candidate in Healthy Middle Eastern Adults: a dose-escalation, open-label, non-randomised, phase 1b trial
ανά: Bosaeed, M, κ.ά.
Έκδοση: (2021)

Effect of Prior ChAdOx1 COVID-19 Immunisation on T-Cell Responses to ChAdOx1-HBV
ανά: Charlotte Davis, κ.ά.
Έκδοση: (2024-06-01)

A single dose of ChAdOx1 Chik vaccine induces neutralizing antibodies against four chikungunya virus lineages in a phase 1 clinical trial
ανά: Pedro M. Folegatti, κ.ά.
Έκδοση: (2021-07-01)

Differential immunogenicity between HAdV-5 and chimpanzee adenovirus vector ChAdOx1 is independent of fiber and penton RGD loop sequences in mice
ανά: Dicks, M, κ.ά.
Έκδοση: (2015)

Design, Immunogenicity and Preclinical Efficacy of the ChAdOx1.COVconsv12 Pan-Sarbecovirus T-Cell Vaccine
ανά: Edmund G.-T. Wee, κ.ά.
Έκδοση: (2024-08-01)

Safety and Immunogenicity of Adenovirus and Poxvirus Vectored Vaccines against a Mycobacterium Avium Complex Subspecies
ανά: Pedro M. Folegatti, κ.ά.
Έκδοση: (2021-03-01)

Humoral immunogenicity and efficacy of a single dose of ChAdOx1 MERS vaccine candidate in dromedary camels
ανά: Alharbi, N, κ.ά.
Έκδοση: (2019)

Humoral Immunogenicity and Reactogenicity of the Standard ChAdOx1 nCoV-19 Vaccination in Taiwan
ανά: Jer-Hwa Chang, κ.ά.
Έκδοση: (2022-02-01)

Comparative effectiveness and safety of homologous two-dose ChAdOx1 versus heterologous vaccination with ChAdOx1 and BNT162b2
ανά: Hermosilla, E, κ.ά.
Έκδοση: (2022)

Safety and immunogenicity of a replication deficient simian adenoviral vectored chikungunya vaccine: A phase I, first-in-human, dose escalation trial
ανά: Folegatti, PM, κ.ά.
Έκδοση: (2019)

Association of Reactogenicity with Immunogenicity of the ChAdOx1 nCoV-19 Vaccine in Patients Undergoing Hemodialysis
ανά: Ting-Yun Lin, κ.ά.
Έκδοση: (2022-08-01)

HBV001: Phase I study evaluating the safety and immunogenicity of the therapeutic vaccine ChAdOx1-HBV
ανά: Tamsin Cargill, κ.ά.
Έκδοση: (2023-11-01)

Immunogenicity and safety of an intradermal ChAdOx1 nCoV-19 boost in a healthy population
ανά: Nawamin Pinpathomrat, κ.ά.
Έκδοση: (2022-05-01)

Durability of ChAdOx1 nCov-19 vaccination in people living with HIV
ανά: Ogbe, A, κ.ά.
Έκδοση: (2022)

Comparative effectiveness and safety of homologous two-dose ChAdOx1 versus heterologous vaccination with ChAdOx1 and BNT162b2
ανά: Eduardo Hermosilla, κ.ά.
Έκδοση: (2022-03-01)

Immunogenicity and efficacy of Zika virus envelope domain III in DNA, protein, and ChAdOx1 adenoviral-vectored vaccines
ανά: López-Camacho, C, κ.ά.
Έκδοση: (2020)

Immunogenicity and Efficacy of Zika Virus Envelope Domain III in DNA, Protein, and ChAdOx1 Adenoviral-Vectored Vaccines
ανά: César López-Camacho, κ.ά.
Έκδοση: (2020-06-01)

Is the ChAdOx1 Vaccine Safe and Immunogenic as Prophylactic Measure Against the Lethal Human-Coronaviruses? A Systematic Review
ανά: Andréia Michelle Alves Cunha de Alcântar, κ.ά.
Έκδοση: (2023-07-01)

Durability of ChAdOx1 nCoV-19 vaccination in people living with HIV
ανά: Ane Ogbe, κ.ά.
Έκδοση: (2022-04-01)

Impact of ChAdOx1 or DNA Prime Vaccination on Magnitude, Breadth, and Focus of MVA-Boosted Immunogen-Specific T Cell Responses
ανά: Alex Olvera, κ.ά.
Έκδοση: (2024-03-01)

Author Correction: Immunogenicity and safety of an intradermal ChAdOx1 nCoV-19 boost in a healthy population
ανά: Nawamin Pinpathomrat, κ.ά.
Έκδοση: (2022-09-01)

Safety and immunogenicity of CoronaVac and ChAdOx1 heterologous prime-boost vaccines in an overweight population in Chiang Mai, Thailand
ανά: Kriangkrai Chawansuntati, κ.ά.
Έκδοση: (2024-06-01)

Safety and Immunogenicity of the Heterosubtypic Influenza A Vaccine MVA-NP+M1 Manufactured onthe AGE1.CR.pIX Avian Cell Line
ανά: Folegatti, P, κ.ά.
Έκδοση: (2019)

Simian adenoviruses as vaccine vectors
ανά: Morris, S, κ.ά.
Έκδοση: (2016)

Simian adenoviruses as vaccine vectors
ανά: Morris, S, κ.ά.
Έκδοση: (2016)

Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial
ανά: Folegatti, PM, κ.ά.
Έκδοση: (2020)